Journal of Clinical & Experimental Immunology
March 3, 2021
1 citation
Depression and post-traumatic stress disorder (PTSD), in the past two decades, has been a growing problem among adults and our youth. For hundreds, if not thousands of years, plant-based psychedelic drugs, such as psilocybin and peyote, have been utilized for medical purposes by numerous native tribal people As early as 1950, lysergic acid diethylamide (LSD), a synthetic mood-altering drug, a...
Journal of Psychopharmacology
March 1, 2021
Antonio Inserra, Danilo de Gregorio, Tamim Rezai et al.
42 citations
Background: The reticular thalamus gates thalamocortical information flow via finely tuned inhibition of thalamocortical cells in the mediodorsal thalamus. Brain imaging studies in humans show that the psychedelic lysergic acid diethylamide (LSD) modulates activity and connectivity within the cortico-striato-thalamo-cortical (CSTC) circuit, altering consciousness. However, the...
The Journal of Clinical Psychiatry
February 23, 2021
Avinash Hosanagar, Joseph Cusimano, Rajiv Radhakrishnan
1 citation
P sychedelics have recently gained attention as compounds with therapeutic potential in the treatment of psychiatric disorders.The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designations for (±)-3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy in severe posttraumatic stress disorder (PTSD) (in 2017) and for the adjunctive use of psilocybin with...
Neuroimage
February 15, 2021
Andrea I. Luppi, Robin Carhart-Harris, Leor Roseman et al.
186 citations
Investigating changes in brain function induced by mind-altering substances such as LSD is a powerful method for interrogating and understanding how mind interfaces with brain, by connecting novel psychological phenomena with their neurobiological correlates. LSD is known to increase measures of brain complexity, potentially reflecting a neurobiological correlate of the especially rich...
bioRxiv Preprint Server
February 4, 2021
Ramona M. Rodriguiz, Vineet Nadkarni, Christopher R. Means et al.
7 citations
preprint
Recent evidence suggests that psychedelic drugs can exert beneficial effects on anxiety, depression, and ethanol and nicotine abuse in humans. However, the hallucinogenic side-effects of psychedelics often preclude their clinical use. Lysergic acid diethylamide (LSD) is a prototypical hallucinogen and its psychedelic actions are exerted through the 5-HT2A serotonin receptor (5-HT2AR). 5-HT2AR...
Journal of Psychedelic Studies
February 4, 2021
R. Andrew Yockey, Keith A. King
64 citations
Abstract We sought to estimate the prevalence of lifetime psilocybin use among a national sample of US adults ages 18 and older and associated demographic/substance use correlates. Pooled data from the 2015–2018 National Survey on Drug Use and Health were utilized among 168,650 individuals 18 years or older. An estimated 9.68% of individuals reported lifetime use of psilocybin. Differences were...
Neuroimage
January 29, 2021
Beatrice M. Jobst, Selen Atasoy, Adrián Ponce-Alvarez et al.
37 citations
Lysergic acid diethylamide (LSD) is a potent psychedelic drug, which has seen a revival in clinical and pharmacological research within recent years. Human neuroimaging studies have shown fundamental changes in brain-wide functional connectivity and an expansion of dynamical brain states, thus raising the question about a mechanistic explanation of the dynamics underlying these alterations....
International Journal of Drug Policy
January 28, 2021
Dimitrios Liokaftos
17 citations
Microdosing psychedelics is the regular use of sub-perceptive threshold doses of substances such as lysergic acid diethylamide (LSD) and psilocybin ('magic') mushrooms. The phenomenon has attracted increasing public and scientific attention in numerous countries in recent years. This commentary looks at microdosing psychedelics as an emerging facet of human enhancement through drugs. After...
Proceedings of the National Academy of Sciences
January 25, 2021
Danilo de Gregorio, Jelena Popić, Justine P. Enns et al.
137 citations
Clinical studies have reported that the psychedelic lysergic acid diethylamide (LSD) enhances empathy and social behavior (SB) in humans, but its mechanism of action remains elusive. Using a multidisciplinary approach including in vivo electrophysiology, optogenetics, behavioral paradigms, and molecular biology, the effects of LSD on SB and glutamatergic neurotransmission in the medial...
Journal of the Academy of Consultation-Liaison Psychiatry
January 21, 2021
Brian S. Barnett, George Greer
13 citations
BackgroundPsychedelic compounds such as lysergic acid diethylamide (LSD), psilocybin, and 3,4-Methylenedioxymethamphetamine (MDMA) share a long and complex history with psychiatry. A half century ago, psychedelics were widely employed by psychiatrists in investigational and clinical settings, with studies demonstrating promising findings for their use in the treatment of mental illness and...
Pharmacopsychiatry
January 20, 2021
Lea J. Mertens, Katrin H. Preller
63 citations
Abstract Classical psychedelics, primarily psilocybin and lysergic acid diethylamide (LSD), have been used and extensively studied in Western medicine as part of substance-assisted psychotherapy in the 1950s and 1960s. Modern clinical research is currently gaining momentum and provides new evidence for the safety and efficacy of classical psychedelics (primarily psilocybin, but also LSD and...
Journal of Psychopharmacology
January 9, 2021
Alan K. Davis, Frederick S. Barrett, Sara So et al.
166 citations
Background: Several measures have been developed to examine acute psychedelic effects (e.g. mystical-type and challenging experiences), but no measure assesses acute psychologically insightful experiences that may occur during psychedelic experiences. Aim: The purpose of this study was to develop and examine the psychometric properties of the Psychological Insight Questionnaire. Method: A...
Revista Criminalistica e Medicina Legal
2021
Luciano C Arantes, Bruno Leite, Luisa Ferreira
12 citations
A dietilamida do ácido lisérgico é uma das substâncias alucinógenas mais potentes já sintetizadas. Sua sigla, LSD, vem do alemão: Lysergsäurediethylamid. O LSD é sintetizado a partir do ácido lisérgico, produzido pelo fungo parasita esporão-do centeio (Claviceps purpurea), nome alusivo ao seu corpo de frutificação e ao principal cereal hospedeiro. O LSD tem afinidade por receptores...
The Alkaloids: Chemistry and Biology
2021
Nikhil R. Tasker, Peter Wipf
32 citations
While the use of ergot alkaloids in folk medicine has been practiced for millennia, systematic investigations on their therapeutic potential began about 100 years ago. Subsequently, Albert Hofmann's discovery of lysergic acid diethylamide (LSD) and its intense psychedelic properties garnered worldwide attention and prompted further studies of this compound class. As a result, several natural...
International Journal of Drug Policy
2021
Liridona Gashi, Sveinung Sandberg, Willy Pedersen
170 citations
We study the significance of stories about bad trips among users of psychedelics. Drawing on narrative theory, we describe the characteristics of such stories and explore the work they do. In-depth qualitative interviews with 50 Norwegian users of psychedelics. Almost all participants had frightening experiences when using psychedelics and many described these as bad trips. The key feature of a...
Frontiers in Psychiatry
2021
Sylvana Vilca-Melendez, Malin V. Uthaug, Julian L Griffin
5 citations
While psychedelics may have therapeutic potential for treating mental health disorders such as depression, further research is needed to better understand their biological effects and mechanisms of action when considering the development of future novel therapy approaches. Psychedelic research could potentially benefit from the integration of metabonomics by proton nuclear magnetic resonance...